Current Drug Regulatory Status of Advanced Drug Evaluation System in Korea

被引:0
|
作者
Pork I.-S. [1 ]
Kim D.S. [2 ]
机构
[1] Pharmaceutical Standardization and Cardiovascular Drug Division, Drug Evaluation Department, Korea Food and Drug Administration, Seoul
[2] Toxicological Research Department, National Institute of Toxicological Research, Korea Food and Drug Administration, Seoul, 122-70, 194 Tongiro, Eunpyeong-gu
关键词
CTD; Drug approval; GMP; GRP; IND; KFDA; Korea;
D O I
10.1177/009286150904300108
中图分类号
学科分类号
摘要
The pharmaceutical industry is a high-risk and high value-added industry, because the risk of failure in research and development is considerable. However, successful development will allow a company to get high returns. The market scale of the pharmaceutical industry has been increasing in the world and the Korean market is changing to focus on quality of life drugs owing to people's increased income levels and changing lifestyles. Drug products are important for the prevention, diagnosis, and treatment of diseases, and the development of drug products has resulted in improved quality of life, health maintenance, and considerable benefits to individuals as well as the national economy. However, since drug products carry the risks of adverse reactions, they have to satisfy the two important criteria of safety and efficacy. Therefore, the Korean government has implemented a drug safety management system, including one for authorization of drug products. Recently, one of the most important issues in the Korean pharmaceutical industry has been the signing of the Korea-US FTA (Free Trade Agreement), which will promote rapid and widespread competition. The pharmaceutical industry will also face the challenges of a more competitive environment. For sustainable growth and development of the Korean pharmaceutical industry in this rapidly changing environment, the balanced harmonization of the industry's strategic R&S efforts and the government's positive policies is essential. © 2009, Drug Information Association. All rights reserved.
引用
收藏
页码:41 / 46
页数:5
相关论文
共 50 条
  • [31] Self Regulatory Drug Transport: An Intelligent Drug Delivery System
    Jain, Ashish
    Mohanty, Pradeep Kumar
    ARS PHARMACEUTICA, 2018, 59 (03) : 173 - 183
  • [32] CURRENT ISSUES IN REGULATORY REQUIREMENTS OF DRUG STABILITY
    CHOW, SC
    PONG, AP
    JOURNAL OF FOOD AND DRUG ANALYSIS, 1995, 3 (02) : 75 - 85
  • [33] Transdermal Drug Delivery System: Current Status and Clinical Application of Microneedles
    Xue, Yanan
    Chen, Cheng
    Mi, Xiangyu
    Tan, Rong
    Wang, Ji
    Wu, Sufan
    Wang, Yue
    Xiong, Rong
    Chen, Mengxiao
    Tan, Wei-Qiang
    Lu, Haojian
    ACS MATERIALS LETTERS, 2024, 6 (03): : 801 - 821
  • [34] CURRENT TOPICS IN CANADIAN DRUG REGULATORY AFFAIRS
    APSE, J
    FOOD AND DRUG LAW JOURNAL, 1976, 31 (01): : 11 - 16
  • [35] Current Development in the Evaluation Methods of Pulmonary Drug Delivery System
    Shaji, Jessy
    Shaikh, M.
    INDIAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2016, 78 (03) : 294 - 306
  • [36] How to integrate drug Information: Korea Drug Utilization Review System
    Yoon, Jeong Sik
    Yi, Byoung-Kee
    Lee, Young Gon
    Kim, Il Kon
    INTERNATIONAL JOURNAL OF INTEGRATED CARE, 2018, 18
  • [37] SCIENTIFIC AND REGULATORY PERSPECTIVES ON DRUG INTERACTION EVALUATION DURING DRUG DEVELOPMENT
    Zhang, Lei
    DRUG METABOLISM REVIEWS, 2014, 45 : 18 - 18
  • [38] THE DRUG REGULATORY SYSTEM - REFLECTIONS AND PREDICTIONS
    CROUT, JR
    FOOD AND DRUG LAW JOURNAL, 1981, 36 (03): : 106 - 119
  • [39] IMPROVING THE GENERIC DRUG REGULATORY SYSTEM
    BENSON, JS
    FOOD AND DRUG LAW JOURNAL, 1990, 45 (03): : 207 - 217
  • [40] THE AUSTRALIAN DRUG REGULATORY SYSTEM - REPLY
    DUKES, MNG
    LUNDE, I
    MEDICAL JOURNAL OF AUSTRALIA, 1982, 2 (09) : 408 - 408